Table 2.
Body weight and heart and aorta weight relative to body weight, urinary albumin, thromboxane B2, 8-isoprostane F2α, malondialdehyde, and nitrate/nitrite during ANG II infusion for 12–14 days: effects of oral tBHQ in Nrf2 mice infused with ANG II for 12–14 days
| Vehicle |
tBHQ |
Effects via ANOVA |
|||||
|---|---|---|---|---|---|---|---|
| Parameter | Nrf2+/+ | Nrf2−/− | Nrf2+/+ | Nrf2−/− | Nrf2 | tBHQ | Interaction |
| Body weight, g | 32.7 ± 1.6 | 31.6 ± 1.2 | 28.5 ± 1.3 | 28.8 ± 0.8 | NS | P < 0.05 | NS |
| Heart/body weight, mg/g | 4.7 ± 0.1 | 4.6 ± 0.1 | 4.4 ± 0.1 | 4.3 ± 0.3 | NS | NS | NS |
| Aorta/heart, % | 32 ± 1 | 32 ± 2 | 34 ± 1 | 33 ± 1 | NS | NS | NS |
| Urinary albumin, µg/mg creatinine | 54.7 ± 3.8 | 56.1 ± 4.9 | 35.6 ± 3.3† | 52.5 ± 8.9 | NS | P < 0.05 | P < 0.05 |
| Urinary TxB2, ng/mg creatinine | 1.59 ± 0.0.07 | 1.54 ± 0.08 | 1.10 ± 0.04† | 1.41 ± 0.08 | NS | P < 0.05 | P < 0.05 |
| Urinary 8-Iso F2α, ng/mg creatinine | 2.86 ± 0.21 | 2.65 ± 0.31 | 1.40 ± 0.06† | 2.19 ± 0.21 | NS | P < 0.05 | P < 0.05 |
| Urinary MDA, mmol/mg creatinine | 81.1 ± 10.3 | 84.4 ± 8.1 | 48.4 ± 2.3† | 88.3 ± 9.1 | NS | P < 0.05 | P < 0.05 |
| Urinary NOx, nmol/mg creatinine | 153 ± 13 | 148 ± 7 | 208 ± 13† | 134 ± 11 | NS | P < 0.05 | P < 0.05 |
Values are expressed as means ± SE values (n = 6 per group) for results obtained at days 12–14 of infusion of ANG II. MDA, malondialdehyde; tBHQ, tert- butylhydroquinone; NOx, nitrite/nitrate; NS, not significant.
†
P < 0.05, compared with vehicle.